DeepMed Research

ASTELLAS PHARMA EUROPE LTD.

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.astellas.com/eu

Clinical Trials

A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment

Phase 4

Completed

Conditions: Non-diabetic Painful Peripheral Polyneuropathy
Peripheral Nerve Injury (PNI)
Postherpetic Neuralgia (PHN)

Interventions: Drug: Qutenza
Drug: Pregabalin

First Posted Date: 2012-10-24

Last Posted Date: 2018-04-23

Lead Sponsor: Astellas Pharma Europe Ltd.

Target Recruit Count: 568

Registration Number: NCT01713426

Locations: 🇹🇷
Site 325 Pamukkale University Medical Faculty Hospital, Denizli, Turkey
🇫🇮
Site 163 ORTON Invalidisaatio, Helsinki, Finland
🇬🇷
Site 203 Aretaieio/Maginio Hospital, Athens, Greece

and more 95 locations

Vesitirim™ in Men Postmarketing Observational Study

Completed

Conditions: Lower Urinary Tract Symptoms (LUTS)
Overactive Bladder (OAB)

Interventions: Drug: Vesitirim™ (Solifenacin)

First Posted Date: 2012-07-13

Last Posted Date: 2013-01-17

Lead Sponsor: Astellas Pharma Europe Ltd.

Target Recruit Count: 12

Registration Number: NCT01639794

Locations: 🇮🇪
Site: 1 - St James Hopsital, Dublin, Ireland
🇮🇪
Site: 3 - Sligo General Hospital, Sligo, Ireland
🇮🇪
Site: 4 - Tallaght Hospital, Dublin, Ireland

and more 2 locations

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.

Phase 3

Completed

Conditions: Urologic Diseases
Urinary Bladder, Overactive
Urinary Bladder Diseases

Interventions: Drug: Mirabegron
Drug: Solifenacin succinate

First Posted Date: 2012-07-11

Last Posted Date: 2024-11-21

Lead Sponsor: Astellas Pharma Europe Ltd.

Target Recruit Count: 1887

Registration Number: NCT01638000

Locations: 🇦🇲
Site: 37404, Yerevan, Armenia
🇦🇲
Site: 37402, Yerevan, Armenia
🇦🇹
Site: 43013, Linz, Austria

and more 214 locations

A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time

Phase 2

Completed

Conditions: Heart Transplantation
Kidney Transplantation
Liver Transplantation

Interventions: Drug: Tacrolimus prolonged release
Drug: Tacrolimus

First Posted Date: 2012-06-08

Last Posted Date: 2024-11-01

Lead Sponsor: Astellas Pharma Europe Ltd.

Target Recruit Count: 44

Registration Number: NCT01614665

Locations: 🇫🇷
Site FR32, Paris Cedex 15, France
🇨🇿
Site CZ61, Prague 5, Czechia
🇫🇷
Site FR33, Bron Cedex, France

and more 7 locations

An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics

Phase 1

Terminated

Conditions: Overactive Bladder
Healthy Subjects

Interventions: Procedure: High resolution urodynamic assessment
Procedure: Conventional urodynamic assessment

First Posted Date: 2012-02-29

Last Posted Date: 2014-10-15

Lead Sponsor: Astellas Pharma Europe Ltd.

Target Recruit Count: 6

Registration Number: NCT01540786

Locations: 🇳🇱
Maastricht University Medical Center, Maastricht, Netherlands

A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation

Phase 4

Completed

Conditions: Liver Transplantation
Kidney Transplantation
Heart Transplantation

Interventions: Drug: Tacrolimus granules

First Posted Date: 2011-06-10

Last Posted Date: 2024-11-01

Lead Sponsor: Astellas Pharma Europe Ltd.

Target Recruit Count: 52

Registration Number: NCT01371331

Locations: 🇩🇪
Site 30, Heidelberg, Germany
🇩🇪
Site 31, Hannover, Germany
🇫🇷
Site: 60, Bron Cedex, France

and more 7 locations

A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients

Phase 4

Terminated

Conditions: Heart Transplantation
Kidney Transplantation
Liver Transplantation

Interventions: Drug: Tacrolimus capsules
Drug: Tacrolimus granules

First Posted Date: 2011-06-10

Last Posted Date: 2024-11-01

Lead Sponsor: Astellas Pharma Europe Ltd.

Target Recruit Count: 47

Registration Number: NCT01371344

Locations: 🇧🇪
Site BE40 Clinique Univ. Saint Luc, Brussels, Belgium
🇫🇷
Site FR60 Groupement Hospitalier EST, Bron, France
🇩🇪
Site DE31 Kliniken der Medizinischen Hoc, Hannover, Germany

and more 9 locations

Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Phase 2

Active, not recruiting

Conditions: Heart Transplantation
Intestine Transplantation
Lung Transplantation
Liver Transplantation
Kidney Transplantation

Interventions: Drug: Tacrolimus
Drug: Tacrolimus prolonged release

First Posted Date: 2011-02-11

Last Posted Date: 2025-04-11

Lead Sponsor: Astellas Pharma Europe Ltd.

Target Recruit Count: 81

Registration Number: NCT01294020

Locations: 🇵🇱
Site PL51, Warsaw, Poland
🇫🇷
Site FR33, Paris Cedex 15, France
🇩🇪
Site DE41, Heidelberg, Germany

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy